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ligand	 CXCL12	 (SDF‐1α).	 The	 involvement	 of	 human	 CXCR4	 in	 several	 pathological	
conditions	 including	 HIV/AIDS	 and	 cancer	 has	 stimulated	 the	 search	 for	 small‐molecule	
CXCR4	 antagonists.	 Cyclopentapeptides	 based	 on	 the	 Arg1‐Arg2‐2‐Nal3‐Gly4‐D‐Tyr5	
sequence	are	potent	CXCR4	antagonists,	and	an	excellent	starting	point	for	development	of	
peptidomimetics,	 i.e.	 compounds	 that	 contain	 non‐peptidic	 structural	 elements	 and	 are	
capable	of	mimicking	the	biological	action	of	a	natural	parent	peptide.	
In	the	present	project,	the	pharmacophore	for	the	lead	cyclopentapeptide	CXCR4	antagonist	




Encouraged	by	 this	SAR	data,	which	suggest	 that	 the	activity	of	cyclopentapeptide	CXCR4	
antagonists	mainly	resides	in	the	tripeptide	D‐/L‐Arg‐L‐Arg‐2‐Nal	fragment,	a	novel	class	of	
scaffold‐based	 tripeptidomimetics	 were	 next	 designed	 and	 synthesized.	 These	 prototype	
tripeptidomimetics	 were	 found	 to	 represent	 new	 peptidomimetic	 hits,	 and	 subsequent	
studies	aiming	to	optimize	the	prototype	compounds	have	been	pursued.		
Finally,	 the	 binding	 mode	 for	 the	 known	 tripeptidic	 CXCR4	 antagonist	 KRH‐1636	 was	
investigated	 through	a	 ternary	strategy	combining	SAR‐,	 site‐directed	mutagenesis	 (SDM)	
studies,	and	molecular	docking	to	the	X‐ray	structure	of	CXCR4.	Comparison	of	the	derived	












A	 number	 of	 important	 physiological	 and	 biochemical	 functions	 of	 life	 are	 influenced	 by	
peptides.	Endogenous	peptides	are	involved	as	neurotransmitters,	neuromodulators	and	as	









Peptide	 mimetics	 can	 be	 developed	 from	 a	 bioactive	 peptide	 precursor	 is	 a	 systematic	
manner,	 and	 this	 thesis	 describes	 the	 ligand‐based	 design,	 synthesis,	 and	 SAR	 for	 small‐
molecule	 mimics	 derived	 from	 a	 lead	 cyclopentapeptide	 antagonist	 for	 the	 G	 protein‐
coupled	chemokine	receptor	CXCR4.	Moreover,	this	project	extends	to	provide	insights	into	
ligand‐receptor	 interactions	 by	 investigating	 the	 binding	 mode	 of	 a	 known	 potent	
tripeptidomimetic	CXCR4	antagonist.		
	An	introduction	to	various	concepts	and	approaches	applied	in	drug	design	is	provided	in	










structure	 or	 origin	 into	 one	 or	more	 categories.	 Protein‐based	 drugs	 (biologic	 agents),12	
peptides,	and	small	organic	molecule13,	14	drugs	represent	some	prominent	examples.	
Drug	 development	 involves	 the	 discovery	 or	 design	 of	 chemical	 compounds	 that	 interact	
with	 a	 biological	 target	 to	 produce	 a	 beneficial	 effect.	 The	 pharmaceutical	 industry	 has	
embraced	 more	 automated	 drug	 discovery‐approaches	 such	 as	 high‐throughput	 organic	
synthesis	and	high‐throughput	screening	(HTS)	of	large	numbers	of	compounds	to	a	great	
extent.15	However,	 the	 approach	 of	 screening	more	 and	more	 compounds	 at	 increasingly	
faster	 rates	has	not	 turned	as	 fruitful	 as	 the	 industry	hoped.16	Drug	development	 is	 slow	
and	expensive;	 in	 the	rare	 instances	that	a	drug	makes	 it	 through	phase	I	clinical	 trials,	 it	
was	 estimated	 to	 cost	 the	 manufacturer	 close	 to	 a	 billion	 US	 dollars.9	 The	 current	 drug	
discovery	paradigm	can	be	synopsized	in	early	phases	comprising	hit‐identification,	hit‐to‐




useful	 source	 to	 initiate	 a	 medicinal	 chemistry	 program,	 while	 `leads´	 represent	 the	





drug	 candidates	 are	 optimized	 leads	 which	 fulfill	 all	 stereoelectronic,	 physicochemical,	
pharmacokinetic	and	toxicologic	requirements	for	clinical	usefulness.17		
2.1.1	A	change	of	course	in	drug	development	
In	 order	 to	 improve	 the	 quality	 of	 the	 compounds	
entering	 the	 initial	 screening,	 rather	 than	 focusing	
directly	 on	 obtaining	 good	 drug	 `candidates,´	 the	
current	 focus	 in	 drug	 discovery	 is	 on	 doing	 things	
earlier	 by	 obtaining	 better	 quality	 `leads.´15,	 18	
Important	 steps	 towards	 obtaining	 better	 lead	
compounds	include	the	use	of	Lipinski´s	rule‐of‐five,	
and	 the	 embodiment	 of	 alternative	 approaches	
summarized	in	“Rational	drug	design”.	
	A	prominent	analysis	by	Lipinski	et	al.19	showed	that	historically	90%	of	orally	absorbed	
drugs	 are	 far	 more	 likely	 to	 fall	 into	 a	 category	 determined	 by	 a	 limited	 range	 of	
physicochemical	 properties	 (rule‐of‐five;	 see	 box).	 Various	 modifications	 and	 alternative	
definitions	have	been	proposed	since	Lipinski’s	rule‐of‐five,20‐22	however	all	agreeing	 that	
drug‐likeness	is	determined	by	a	set	of	molecular	properties	and	descriptors.	
Rational	 drug	 design	 represents	 an	 alternative	 strategy	 to	 the	 empirically	 based	 high‐
throughput	synthesis	and	‐screening.	In	this	approach,	bioactive	compounds	are	specifically	






The	molecular	 recognition	 of	 ligand	 with	 the	 target	 is	 an	 essential	 event	 for	 inducing	 a	
biological	response.	23	Most	of	the	current	approaches	in	rational	drug	design	may	fall	into	
two	main	 categories:	 ligand‐based	 and	 structure‐based	design.	 The	 common	goal	 of	 both	
Rule‐of‐five:	 	 poor	 absorption	 or	
permeation	 are	 more	 likely	 when	
cLogP	 (the	 calculated	 1‐octanol–
water	 partition	 coefficient)	 is	 >5;	
molecular	 mass	 is	 >500	 g/mol;	 the	
number	of	H‐bond	donors	 (OH	plus	
NH	count)	 is	>5;	and	the	number	of	









ligand.	 In	 ligand‐based	 design,	 one	 proceeds	 from	 a	 parent	 compound	 (bioactive	 `hit´	
ligand)	 with	 no	 information	 about	 the	 receptor	 to	 eventually	 determine	 the	
pharmacophore,	i.e.	the	ensemble	of	features	(steric	and	electronic)	necessary	for	a	drug	to	
possess	in	order	to	ensure	optimal	interactions	with	the	target.24				
	Experimental	 SAR	 studies	 constitute	 an	 important	 part	 in	 this	 process,	 and	 if	 a	
conformationally	 constrained	molecule	 is	 biologically	 active,	 it	may	 serve	 to	 identify	 the	
spatial	 orientation	 of	 the	 pharmacophoric	 groups.	 Aside	 from	 pharmacophore	 modeling	
(and	 thereafter	 screening	 for	 potential	 `hit´	 candidates),	 computationally	 assisted	 ligand‐
based	drug	design	often	includes	quantitative	structure‐activity	relationship	(QSAR)	studies	
in	order	to	provide	key	insights	into	potentially	favorable	ligand‐receptor	interactions.	This	
further	enables	 the	 construction	of	 suitable	and	predictive	models	 for	 lead	discovery	and	
optimization.25	
Challenges	 include	 the	 difficulty	 to	 determine	 a	 3D‐pharmacophore	 due	 to	 the	 inherent	
conformational	 flexibility	of	 the	 ligands	 (as	 they	exist	under	physiological	 conditions	as	a	
mixture	 of	 interconverting	 conformations).	 This	 issue	 can	 often	 be	 dealt	 with	 by	
determining	the	conformational	space	available	to	a	given	ligand,	i.e.	by	consideration	of	the	






energy	 conformation.29	 Accordingly,	 placing	 the	 ligand	 in	 a	 conformation	 that	 is	 more	













to	 identify	 and	 optimize	 drug	 candidates,	 i.e.	 by	 examining	 and	 modeling	 molecular	
interactions	 between	 ligands	 and	 target	 macromolecules.	 Scoring	 functions	 are	 applied	
during	 docking	 to	 evaluate	 the	 interactions	 (binding	 free	 energy)	 and	 rank	 the	 resulting	
conformations.	 In	 this	 way,	 a	 filtering	 criterion	 is	 provided	 to	 allow	 focus	 on	 the	 most	
promising	candidates	for	ligand	optimization.		
However,	 resolved	 crystal	 structures	 (especially	 for	 membrane‐bound	 targets)	 are	 often	
not	available.	Alternatively,	information	about	ligand‐receptor	interactions	can	be	obtained	
through	SDM.	Computational	approaches	to	produce	a	representative	model	of	the	receptor	
(homology	 modeling	 or	 de	 novo	 automated	 design,	 see	 section	 3.3)	 are	 also	 used.	 Both	
approaches	have	disadvantages	compared	to	the	use	of	input	from	resolved	structures	(X‐
ray,	NMR);	mutational	mapping	 (SDM)	of	 ligand‐receptor	 interactions	may	 lead	 to	biased	
information	 due	 to	 protein	 structure‐rearrangements	 upon	mutagenesis,	while	 homology	
models	alone	are	suboptimal	and	less	accurate	representations.	
	Evidently,	challenges	within	ligand‐based	or	structure‐based	design	are	often	resolved	by	
combination	 of	 strategies	 to	 include	 several	methodologies,	 e.g.	 experimental:	 (SAR‐	 and	



















(5‐50	 a.a:	 ~500‐5000	 Da)	 to	 discriminate	 them	 from	 small	 organic	 molecule	 (<500	 Da)	
drugs	and	protein	based	drugs	(biologics)	of	>5000	Da.32	
At	present,	biologics	constitute	a	large	field	of	the	pharmaceutical	industry	as	a	successful	
class	of	 therapeutics	both	 in	 treating	diseases	but	also	 from	an	economic	perspective	 (i.e.	
Humira	Pen	and	Enbrel	in	rheumatoid	arthritis	(RA)	treatment	with	estimated	worldwide	
sales	of	9.48	and	8.37	billion	dollars	respectively	 in	2012).33	An	 important	reason	 for	 the	
increasing	market	share	of	biologics	is	their	higher	target	specificity	due	to	their	larger	size.	
However,	 there	 are	 also	many	 disadvantages	with	 biologics	 as	 drugs	 such	 as	 the	 lack	 of	
membrane	permeability,	poor	oral	bioavailability,	and	lower	metabolic	stability	compared	
to	 smaller	 molecule	 drugs.	 In	 general,	 biologics	 disobey	 every	 one	 of	 “the‐rule‐of‐five”	
parameters,	19,	34	and	as	expected	they	are	not	suitable	for	oral	administration	and	normally		
require	injection	delivery.	
Compared	 to	 protein	 based	 drugs,	 peptides	 have	 the	 potential	 to	 penetrate	 deeper	 into	
tissues	due	to	their	smaller	size,	and	are	generally	considered	to	be	less	immunogenic.35		







Moreover,	 several	 advantages	 of	 peptides	 over	 small	 organic	 molecule	 drugs	 include	
increased	 selectivity	 and	 specificity	 on	 binding	 the	 desired	 target,36	 and	 since	 their	
degradation	 products	 are	 amino	 acids	 they	 generally	 exhibit	 a	 reduced	 risk	 of	 toxicity.37	
Thus,	peptides	represent	a	class	of	molecules	 that	have	 the	specificity	and	potency	of	 the	
larger	size	biologics,	but	are	smaller	in	size,	more	accessible	and	cheaper	to	produce	using	
chemical	methods.38	Therapeutic	peptides	have	been	traditionally	derived	from:	i)	bioactive	
natural	 peptides	 produced	 by	 plants,	 animals	 or	 humans	 and	 ii)	 isolated	 from	 genetic	 or	
recombinant	 libraries.39,	 40	 However,	 limited	 availability	 of	 tissue	 sources,	 methods	 of	
extraction,	 and	 increased	 risks	 of	 contamination	 are	 reasons	 as	 to	 why	 the	 isolation	 of	
peptides	 from	natural	 sources	 is	 often	 problematic.	 Although	 a	 number	 of	 peptide	 based	
therapeutics	 have	 reached	 the	market,	 their	 development	 as	 drugs	 has	 been	 limited;	 low	





















Once	 the	 structure	 of	 a	 bioactive	 natural	 peptide	
ligand	 is	 known,	 an	 initial	 step	 involves	 the	
identification	 of	 the	 key	 aa‐side	 chain	 residues	
necessary	 for	 receptor	 recognition,	 by	 means	 of	
single	 amino	 acid‐modifications	 in	 the	 ligand.	 This	
process	usually	includes	an	Ala‐scan,48	(step	1,	Figure	
3)	 where	 each	 amino	 acid	 is	 systematically	
substituted	 by	 L‐alanine	 followed	 by	 biological	
activity	 measures	 (SAR	 studies)	 to	 examine	 the	
relative	 importance	 of	 each	 side‐chain	 group.	 To	
obtain	 initial	 information	on	 structural	 arrangement	
or	 identify	 potential	 turn	 inducing	 positions	 (i.e.	
highly	desired	secondary	protein	structure	elements	
for	peptide‐receptor	 interactions)	 in	 the	 sequence,	 a	
D‐scan	 (step	 1,	 Figure	 3)	 can	 be	 performed.	
Accordingly,	 the	 original	 amino	 acids	 (in	 L‐
configuration)	are	replaced	by	their	D‐enantiomers.23	
	3.2.1	Conformational	constraints	
Additionally,	 other	 local	 conformational	 constraints	
(step	3,	Figure	3)	can	be	applied	to	the	ligand	in	order	
to	 constrain	 the	 backbone	 conformation	 (φ,	ψ,	 and	ω	 torsional	 angles,	 see	 Figure	4A)	 to	
more	 energetically	 preferred	 conformations.	 For	 instance,	 N‐methylation	 restricts	 the	
amide	bond	and	allows	 formation	of	a	cis	bond,	while	 isosteric	amide	bond	replacements	
and	α‐substituted	amino	acids	can	induce	favorable	secondary	structures	(α‐helix,	β‐sheet,	
reverse	 turns,	 etc.)	 according	 to	 their	 own	 unique	 stereostructural	 properties,	 often	
including	the	nature	of	the	χ1	group	as	well.49‐51		
	Ultimately,	 the	 introduction	 of	 a	 global	 constraint	 (Figure	 3)	 by	 means	 of	 peptide	
cyclization	 is	a	crucial	step	 in	 the	sense	that	an	appropriate	 template	 for	all	 the	elements	
that	 make	 up	 the	 pharmacophore	 is	 provided.	 Moreover,	 cyclization	 improves	 the	
Figure	3.	Flow‐chart	of	main	steps	 in	a	
systematic	 approach	 for	 drug	 design	
from	 a	 biologically	 active	 peptide.	






pharmacokinetic	 properties	 of	 the	 ligand	
by	 reducing	 H‐bonding	 (rule‐of‐five),	
enhances	 membrane	 permeability,	 and	
increases	 stability	 against	 proteolytic	
degradation.	
3.2.2		3D‐Pharmacophore	determination	
At	 this	 point,	 alternative	 strategies	 to	
determine	 the	 bioactive	 conformation	 and	
3D‐pharmacophore	 model	 (step	 4,	 Figure	
3)	may	 include	 synthesis	 and	 SAR‐studies	
of	 analogues	 of	 the	 cyclic	 peptide.	
Accordingly,	 	 sequential	 alteration	 of	 the	
aa‐sequence	order	 in	combination	with	D‐
scans	 contributes	 to	 identify	 the	 desired	
turn	conformation	in	the	cycle52	as	well	as	
the	 optimal	 stereochemistry	 of	 the	 side‐
chains.	 The	 side‐chain	 groups	 of	 amino	 acid	 residues	 in	 a	 peptide	 generally	 have	 free	
rotation	about	the	side‐chain	torsional	(or	dihedral)	angles	(for	topography	in	χ‐space	see	
Figure	 4A,	 e.g.	 χ1	 for	 Cα‐Cβ	 bond,	 χ2	 for	 Cβ‐Cγ	 bond	 etc.).	 It	 has	 become	 increasingly	
apparent	that	also	the	χ‐angles	(in	conjunction	with	the	backbone	angles	(φ,	ψ)),	are	critical	
for	ligand‐receptor	interactions.47	
	As	 depicted	 in	 Figure	 4B,	 the	 three	 low‐energy	 conformations	 for	 χ1	 are	 referred	 to	 as	
gauche	(‐),	gauche	(+),	and	trans.53,	54	The	challenge	seems	to	lie	in	determining	which	of	the	
three	low‐energy	conformations	the	side‐chains	adopt	upon	binding	to	the	receptor,	i.e.	the	
one	 that	 is	 implicit	 as	 part	 of	 the	 pharmacophore.	 An	 example	 of	 chemical	modifications	
that	can	be	done	to	define	the	χ‐topography,	is	the	restriction	of	the	rotation	around	Cα‐Cβ	
bond	 and	 Cβ‐Cγ	 bond	 by	 incorporating	 the	 side‐chain	 of	 interest	 into	 various	 ring	
structures.	Subsequent	SAR	studies	in	conjunction	with	NMR,	and	computational	methods	
(Molecular	 Mechanics	 and	 ‐Dynamics)	 can	 then	 determine	 the	 topography	 or	 3D	
arrangement	of	critical	side‐chain	groups.	
Figure	4.	A.	Backbone	 torsional	 angles	 (φ,	 ψ,	 ω)	
and	 side‐chain	 dihedral	 angles	 χ‐angles.	 B.		
Newman	 projections	 of	 three	 staggered	 rotamer	




Evidently,	 at	 this	 point	 in	 the	 process	 a	 more	 precise	 3D	 conformation	 of	 the	
pharmacophore	 is	 obtained,	 and	 in	 many	 cases	 highly	 potent	 and	 efficacious	 drug	
candidates	 are	 produced	 in	 the	 process.	 However,	 this	 is	 also	 a	 good	 starting	 point	 for	
development	 of	 peptide	 mimetics	 (or	 peptidomimetics)	 from	 the	 derived	 potent	 cyclic	
peptide	and/or	the	defined	3D	pharmacophore	(step	6,	Figure	3).		
3.3	Design	of	peptidomimetics	
The	 overall	 goal	 with	 peptidomimetic	 drug	 design	 is	 to	 obtain	 ligands	 with	 improved	
pharmacokinetic	 profile.	 Higher	 stability	 to	 biodegradation,	 good	 bioavailability,	 and	
potential	 for	 oral	 delivery	 renders	 the	 peptidomimetic	 class	 of	 compounds	 more	 in	
agreement	 with	 Lipinski`s	 rule‐of‐five,	 than	 their	 peptide	 precursors.	 If	 a	 non‐peptide	
ligand	 is	 desired,	 the	 proper	 choice	 of	 scaffold	 (i.e.	 the	 core	 structure	 of	 the	 molecule	
replacing	the	peptide	backbone)	that	can	place	the	key	side‐chain	residue	in	3D‐space	is	the	
challenge.	The	determination	of	a	scaffold	 is	particularly	 important	 in	de	novo	design17	of	
novel	ligands.55,	56	
When	 a	 3D	 pharmacophore	 or	 a	 receptor‐binding	 site	 is	 known	 then	 it	 is	 possible	 to	
develop	novel	 ligands	with	different	scaffolds.	 Information	extracted	from	ligand‐receptor	
interactions	constitutes	the	primary	criteria	or	constraints,	i.e.	physicochemical	properties	
and	potential	 interaction	points	 that	contribute	to	binding	affinity,	and	 if	 this	 information	
can	be	collected	from	the	3D‐receptor	structure,	the	design	strategy	is	receptor‐based.		
3.3.1	De	novo	structure‐based	design	
Receptor	based	design	using	X‐ray	 input	of	 the	 receptor	 structure	usually	 starts	with	 the	
determination	of	the	binding	site.	Several	de	novo	design	softwares56	exist	with	diversified	
searching	algorithms	and	scoring	criteria;	potentially	all	leading	to	the	determination	of	the	














ligand	 or	 its	 3D	 pharmacophore	 model	 as	 an	 input	 for	 design	 of	 novel	 compounds.	 An	
advantage	with	 this	 approach	 is	 that	 the	 topology	 or	 the	 3D	 conformation	 of	 the	 known	
ligand	 can	 provide	more	 accurate	 information	 in	 the	 starting	 point.	 The	 pharmacophore	
model	 can	be	used	 to	obtain	a	pseudoreceptor	model,	 i.e.	 to	 computationally	generate	an	
artificial	protein	receptor	as	a	replacement	for	the	3D	structure.59,	60	The	models	attempt	to	
capture	the	shape	of	the	binding	site	and	its	interaction	points	for	successful	ligand	binding.	
Accordingly,	 from	 this	 point	 on,	 the	 same	 structure‐based	 strategy	 described	 in	 the	





screening	 methods	 such	 as	 scaffold‐
hopping.61	Scaffold‐hopping	refers	to	the	
identification	 of	 isofunctional	 but	
structurally	 different	 chemotypes	 to	 a	
query	 lead	 ligand	 by	 using	
pharmacophoric	 features	 as	 an	 input,62	
i.e.	 structurally	novel	compounds	can	be	
pursued	 by	 altering	 the	 central	 core	
structure	 or	 template	 of	 a	 known	active	
compound.	 Of	 the	 most	 attractive	
scaffold‐hops	 is	 the	 transition	 from	
peptidic	 ligands	 of	 the	 receptor	 to	 small	 non‐peptide	 mimetics	 of	 the	 peptidic	 ligand	
precursors.	 There	 are	 several	 computational	 approaches	 to	 scaffold‐hopping,	 and	 some	












their	 use	 and	 future	 development	 is	 on	 the	 rise.	 However,	 the	 use	 of	 experimental	 data	
either	 to	 guide	 selection	 of	 	 candidates	 for	 further	 structural	 tuning	 (SAR	 studies)	 or	 to	
determine	starting	conformations	(NMR‐,	X‐ray,	etc.)		of	input	structures	in	computational	
programs	 are	 an	 inherent	 part	 to	 a	 successful	 strategy	 towards	 drug	 design.	 Moreover,	
experimental	determination	of	receptor	binding	sites	by	SDM	studies	often	provides	a	more	
accurate	 input	 on	 side‐chain	 coordinates.	 This	 offers	 a	 higher	 potential	 for	 obtaining	hit‐





does	 not	 reflect	 the	 fact	 that	 GPCRs	 are	 the	 most	 successful	 drug	 targets	 in	 terms	 of	
therapeutic	 benefit	 and	 potential	 sales.64	 GPCRs	 are	 highly	 insoluble	 and	 very	 dynamic;	
their	 structure	 is	 constantly	 changing	 during	 interaction	 with	 ligands	 and	 proteins	
rendering	them	difficult	to	isolate	and	crystallize.9	In	the	absence	of	3D	target	information,	
ligand‐based	design	 is	 still	 the	usual	way	 to	develop	new	drug	 candidates	with	GPCRs	as	









GPCRs	 are	 the	 largest	 family	 of	 membrane	 proteins	 and	 their	 involvement	 in	 signal	
transmission	 is	 fundamental	 for	most	physiological	 conditions,	 ranging	 from	vision,	 smell	
and	 taste	 to	 neurological,	 cardiovascular,	 endocrine	 and	 reproductive	 functions.	
Accordingly,	 the	 GPCR	 superfamily	 is	 a	 main	 target	 for	 therapeutic	 intervention	 and	
represents	the	target	directly	or	indirectly	of	50‐60%	of	all	current	therapeutic	agents.65‐67	
GPCRs	 share	 common	 structural	
elements	 of	 seven	 hydrophobic	
transmembrane	 helices	 (TMHs)	 with	




sequence	 similarity	 within	 their	 7	
TMHs,	 GPCRs	 can	 be	 clustered	 into	 five	 major	 families:	 class	 A	 (the	 rhodopsin),	 class	 B	
(secretin),	 class	 C	 (Glutamate),	 class	 D	 (Fungal	 pheromone),	 class	 E	 (cAMP)	 and	 the	






and	 Glutamate	 (class	 C)	 receptors.70	 Newer	 developments	 in	 the	 area	 of	 X‐ray	
crystallography	accelerated	the	rate	of	resolved	high‐resolution	structures,	and	by	2014	a	
number	 of	 structures	 of	 different	 class	 A	 GPCRs	 has	 been	 determined.	 Most	 of	 these	
receptors	 are	 aminergic	 and	 are	 subclassified	 as	 group	 ‐class	 A	 receptors;	 they	 bind	
acetylcholine	 and	 monoamine	 neurotransmitters	 and	 examples	 include	 ‐adrenergic	




peptide‐binding	 receptors	 (group	 ‐class	 A	 GPCRs)	 have	 been	 solved,	 including	 the	




A	 number	 of	 studies	 have	 suggested	 that	 most	 GPCRs	 exist	 in	 a	 dynamic	 equilibrium	
between	inactive	and	active	states,	and	can	be	further	converted	to	a	signaling	state	in	the	
presence	 of	 heterotrimeric	 G‐proteins.78,	 79	 Comparisons	 of	 active	 and	 inactive‐state	
structures	indicated	common	activation‐related	features	based	on	conformational	changes	
in	the	 intracellular	sides	of	 the	receptors.	Alternatively,	different	GPCR	conformations	are	





“global	 toggle	 switching”,	 claims	 that	 an	 outward	 “swinging”	motion	 of	 TMH	 6	 in	 accord	
with	 TMH	 7	 takes	 place	 upon	 receptor	 activation.86,	 87	 Subsequently,	 ligand‐induced	
activation	 involves	 spatial	 TMH‐rearrangement,	 particularly	 for	 TMHs	 5‐7.81	 Moreover,	




Upon	 ligand	 binding	 to	 GPCRs,	 the	 exposed	 receptor	 intracellular	 sites	 interact	 with	 G‐
protein	heterotrimer	(α,	β,	and	γ	subunits)	which	play	a	crucial	role	in	signal	transduction	
towards	second	messenger	cascades	(Figure	7).	Notably,	the	activation	of	some	GPCRs	also	








and	 separation	 of	 Gα	 from	 Gβγ	 subunits.	 Potential	 contacts	 with	 the	 subunits	 of	 other	





















Chemokines	 (or	 chemotactic	 cytokines)	 are	 a	 family	of	 small	 secreted	proteins	8‐14	kDa,	
and	 through	 their	 receptor	binding	and	mediated	effects,	 they	 control	 immune	responses	
with	an	emphasis	on	leukocyte	trafficking,	and	maturation.91		However,	they	are	also	known	















The	 CXC	 subfamily	 (‐subfamily)	 contains	 two	 cysteine	 residue	 pairs	 forming	 two	 Cys‐
bridges	 separated	 by	 one	 nonconserved	 amino	 acid.	 The	 CC‐	 (‐subfamily)	 contains	 two	
adjacent	 Cys	 residues,	 and	 the	 XC‐	 (‐subfamily)	 contains	 only	 one	 disulfide	 bridge.	
Moreover,	 the	CX3C‐	 (‐subfamily)	 contains	 three	residues	between	 the	 two	Cys	 residues	
and	has	only	one	member	known	 to	date.	All	 chemokines	bear	an	L‐suffix	 to	denote	 that	
they	are	ligands	(e.g.,	CCL1).93		











The	 discovery	 of	 neutrophile‐targeted	
chemokine	IL‐8	(of	the	C‐X‐C	subfamily)	and	its	
structure	 determination	 by	 X‐ray	 and	 NMR‐
studies94,	 95	 gave	 the	 first	 important	 insights	
into	 the	 3D	 secondary	 structure	 elements	 of	
chemokines.	 The	 crystal	 structures94,	 95	
indicated	 a	 heterodimer	 (Figure	 9)	 stabilized	
by	 formation	 of	 six‐stranded	 antiparallel	 ‐
sheet	 (three	 from	 each	 monomer)	 and	 by	
hydrophobic	 interactions	 with	 the	 overlying	
helices.	 Structure‐activity	 relationship	
studies96	 on	 truncated	 analogues	 of	 IL‐8	 indicated	 furthermore,	 the	Glu4‐Leu5‐Arg6	 (ELR)	
motif	as	essential	for	the	binding	and	activity	of	not	only	IL‐8	but	also	for	CXCR1	and	CXCR2	
chemokine	ligands.97	
	Additional	 studies98	 indicated	 that	 residues	 4‐22	 (N‐terminus)	 are	 essential	 for	 receptor	
binding,	and	residues	30‐35	(turn)	contributes	through	a	disulfide	(7‐34)	bridge	(Figure	9)	
to	ensure	correct	conformation	of	the	N‐terminal	region.	Moreover,	some	research	groups99,	
100	 suggested	 the	 monomer	 might	 be	 the	 biologically	 active	 form	 instead	 of	 the	 dimer.	
However,	 the	 possibility	 that	 the	 dimer	 might	 be	 essential	 during	 the	 binding	 was	 not	
excluded.	 In	 general,	 the	 essential	 monomeric	 structural	 fold	 of	 chemokines	 is	 well	
conserved	 consisting	 of	 a	 three‐stranded	 antiparallel	 ‐sheet	 with	 an	 ‐helix	 at	 the	 C‐
terminus.	The	N‐terminus	is	generally	disordered	but	found	important	for	activation.98,	101	
Additionally,	 an	 extended	 loop	 region	 leading	 to	 a	 310‐helix	 turn	 right	 before	 the	‐sheet		
was	also	 reported	as	 important	 for	 the	antiproliferative	 response	of	 the	CCL3	 chemokine	
ligand.102	
Representative	 examples	 of	 the	 CXC‐,	 CC‐,	 XC‐,	 and	 CX3C‐subfamilies	 are	 illustrated	 in	
Figure	10.		























according	 to	 the	class	of	chemokines	 that	 they	bind.	Accordingly,	 they	bear	an	R‐suffix	 to	





chemokine	 receptors	 transduce	 signals	 through	 heterotrimeric	 G‐proteins.106	 However	
Figure	 10.	Representative	 examples	 from	 the	
four	chemokine	subfamilies;	a.	CXCL10	b.	CCL7	
c.	XCL1	d.	 CX3CL1;	Disulfide	bonds	are	shown	









found	 to	 be	 involved	 in	 scavenging	 inflammatory	 chemokines	 from	 the	 extracellular	
microenvironment.107	 With	 the	 discovery	 of	 chemokine	 receptors,	 the	 interest	 in	





However,	 there	 are	many	obstacles	 in	drug	discovery	of	 chemokines;	 one	of	 these	 issues	
concerns	the	lack	of	selectivity	as	many	small‐molecule	antagonists	cross‐react	with	other	
GPCRs.	 Other	 issues	 include	 the	 lack	 of	 relevant	 animal	 models	 and	 the	 nature	 of	 the	













the	 two‐site	 model	 theory.	 In	 brief,	 it	 was	 suggested	 that	 the	 CXCL12‐RFFESH	 loop	 is	
optimal	 for	 the	 initial	binding	or	docking	with	 the	N‐terminus	of	CXCR4	receptor	 (site	 I);	
thus,	 allowing	 access	 to	 the	 more	 buried	 receptor	 site.	 Subsequently,	 the	 N‐terminal	














model	 comes	 from	 the	 recently	 released	X‐ray	 structures	of	CXCR4	by	Wu	et	al.,75	where	
four	 crystal	 CXCR4	 structures	 were	 reported	 bound	 to	 a	 small	 antagonist	 IT1t,	 and	 one	
structure	 bound	 to	 a	 cyclic	 peptide	 CVX15	 (Figure	 12).	 The	 CVX15	 peptide	may	 trace	 to	
some	 extent	 the	 path	 of	 N‐terminal	 peptide	 sequence	 of	 CXCL12	 (KPVSLSYR),	 and	 the	
binding	site	of	IT1t	may	point	to	the	major	anchor	region	for	this	domain.	
The	 small	 ligand	 IT1t	 and	 the	 CVX15	 peptide	 are	 both	 orthosteric	 competitors	 of	 the	








to	 portray	 a	 ligand	 binding	within	 `the	minor	 ligand	 pocket´,75	 (see	 Figure	 13)	while	 the	


























The	 chemokine	 C‐X‐C	 receptor	 4	 (CXCR4)	 is	 comprised	 of	 352	 amino	 acid	 residues,	 and	
displays	33%	homology	to	other	CXC	and	CC	members	of	the	chemokine	receptor	family.117	
CXCR4	has	only	one	known	natural	ligand,	the	68‐mer	chemokine	peptide	CXCL12	(SDF‐1a)	
that	 is	 rich	 in	 basic	 amino	 acids	 (Arg,	 Lys,	 and	 His).	 CXCR4	 itself	 is	 however	 strongly	
negatively	 charged	 in	 comparison	 to	 other	 chemokine	 receptors,118	 and	 has	 an	 overall	
electrostatic	 surface	 charge	 of	 ‐9.	 The	 CXCR4‐CXC12	 axis	 is	 found	 to	 be	 involved	 in	
physiological	 processes,	 such	 as	 the	 homing	 of	 immune	 cells	 (T‐cells)	 to	 sites	 of	




the	 receptor	 was	 initially	 reported	 as	 a	 co‐receptor	 for	 CD4+	 T‐cell	 infection	 of	 human	
immunodeficiency	virus	(HIV)	 type	 I,123	 	and	subsequently	 in	pathogenesis	of	 rheumatoid	
arthritis124	as	well	as	multiple	types	of	cancer.125	Evidently,	the	involvement	of	the	CXCL12‐
CXCR4	system	in	a	wide	range	of	physiological	and	pathological	conditions,	and	its	lack	of	
promiscuity	 is	 of	 increasing	 interest	 in	 drug	 discovery.	 It	 is	 not	 within	 the	 scope	 or	
objectives	of	the	present	thesis	to	comprehensively	cover	the	involvement	of	the	CXCL12‐
CXCR4	 system	 in	 all	 the	 related	 pathologies.	 However,	 a	 brief	 introduction	 in	 the	
mechanisms	involving	CXCL12‐CXCR4	in	HIV‐entry	is	presented	in	the	following	section.	
6.2.1	Role	of	CXCR4	in	HIV	infection	




of	 T‐tropic	 HIV‐1	 strains,	 while	M‐tropic	 HIV‐1	 strains	 preferentially	 use	 CCR5,	 which	 is	
expressed	 in	monocytes‐macrophages.	Moreover,	 other	 viral	 strains	 exhibit	 dual‐tropism	





emerge	 in	 later	 stages	 of	 infection	 and	 are	
associated	 with	 the	 disease	 progression	 to	
AIDS.127,	128	Viral	entry	as	depicted	for	T‐tropic	
strains	 in	 Figure	 15,	 involves	 the	 binding	 of	
the	 trimeric	 gp120	 viral	 envelope	 protein	 to	
the	 CD4	 receptor,	 which	 in	 turn	 induces	 a	
conformational	change	to	allow	binding	of	the	
V3	 loop	 (gp120)	with	 CXCR4.	 CXCL12	 blocks	
T‐tropic	 HIV‐1	 from	 entering	 cells,	 and	 a	
potential	 drug	 target	 is	 therefore	 implicated.	
Several	studies	have	demonstrated	the	ability	
of	 both	 CXCL12	 and	 isoforms	 to	 block	 HIV‐1	
entry	via	CXCR4.101,	 129	However,	 the	use	of	chemokines	as	antiretroviral	agents	 is	 limited	
by	 their	 short	 half‐life	 and	 potential	 undesirable	 inflammatory	 effects.130	 Hence,	 the	
rationale	behind	the	development	of	anti‐HIV	CXCR4‐antagonists	as	drug	candidates,	lies	in	
their	 “non‐signal‐inducing”	 block	 of	 HIV‐entry,	
limiting	 therefore	 undesirable	 inflammatory	
responses.	 Their	 function	 does	 not	 rely	 on	





















A	 number	 of	 CXCR4	 ligands	 have	 been	 described	 over	 the	 years.131‐133	Most	 of	 the	 drug	
discovery	targeting	CXCR4	has	focused	on	the	development	of	antagonists,	and	initially	the	
focus	was	 turned	 toward	 their	 potential	 as	 anti‐HIV	 drugs.	However,	 as	 the	 field	 of	 drug	
research	quickly	 expanded,	 other	disease	 states	were	 shown	 to	 involve	CXCR4	as	well.	A	









HIV‐1	 entry	 to	 the	 cell	 and	 inhibiting	 Ca+2	 mobilization	 normally	 induced	 by	 CXCL12‐
signaling;135‐137	 T140	 forms	 an	 antiparallel	 ‐sheet	 structure	 supported	 by	 a	 disulfide	
bridge	 and	 connected	 by	 a	 II’	 turn138	 (Figure	 16).	 Although	 T140	 was	 found	 unstable	
toward	biodegradation,134,	 139	 the	modified	T140‐analogues	4F‐benzoyl‐TN14003	 and	4F‐
benzoyl‐TE14011	(Figure	16),	displayed	enhanced	biostability	and	anti‐HIV	activity	 (EC50		
values	 0.6	 and	 1.6	 nM	 respectively),134,	 140,	 141	 	 suggesting	 that	 the	 N‐terminal	 4‐
fluorobenzoyl	 moiety	 could	 be	 a	 part	 of	 the	 pharmacophore	 associated	 with	 anti‐HIV	
activity.	 SAR	 studies	 on	T140142	 	 indicated	 furthermore	 the	 four	 amino	 acids	 (Arg2,	Nal3,	
Tyr5,	 and	 Arg14)	 as	 essential	 for	 significant	 activity,	 and	 as	 potential	 pharmacophoric	
residues.	 Following	 studies	 which	 included	 NMR	 analysis	 and	MD‐calculations,	 indicated	
the	four	essential	residues	(see	Figure	16)	of	T140142	to	be	in	close	proximity.	
Subsequently,	 in	 a	 pharmacophore‐based	 approach	 of	 screening	 cyclic	 pentapeptidic	
libraries,143	 the	 potent	 CXCR4	 antagonist	 FC131	 (Figure	 16;	 a	 third	 generation	
polyphemusin	 II‐derivative)	was	discovered,	shown	to	be	equipotent	 to	T140	(IC50	values	
0.004	 M,143).	 Unlike	 T140	 however,	 FC131	 is	 globally	 constrained	 and	 more	 stable	





studies	were	 carried	 out	where	 several	 approaches	 to	 drug	 optimization	were	 employed	
(see	section	3.2),	including:	Ala‐scans,	D‐scans,	N‐methylations,	constraints	through	use	of	
unnatural	 amino	 acids	 and	 isosteric	 replacements.144‐152	 Accordingly,	 derived	 SAR‐data	
have	 shed	 light	 into	 the	 structural	 requirements	 of	 cyclopeptides	 for	 CXCR4	 antagonistic	
activity,	and	 in	some	cases	analogues	with	 improved	potency	were	detected.	 Importantly,	
these	studies	laid	the	foundation	for	future	development	of	more	drug‐like	mimetics	of	the	
cyclic	pentapeptide	prototype	FC131.	
In	 retrospect,	 the	 whole	 body	 of	 work	 from	 polyphemusin	 II	 to	 development	 of	 FC131	


























The	 non‐peptide	 based	 CXCR4	 antagonists	 which	 is	 the	 largest	 and	 most	 structurally	
diverse	category	of	CXCR4	antagonists,	comprises	over	10	different	chemical	classes.132,	133	
An	extensively	studied	representative	in	this	category	is	the	bicyclam	AMD3100	(1,	Figure	
17),	 originally	 regarded	 as	 a	 highly	 potent	 and	 selective	 inhibitor	 in	 HIV	 fusion	 and	
uncoating.153	However,	 in	 subsequent	 clinical	 trials	 it	was	 indicated	 that	AMD3100	 could	
additionally	 mobilize	 various	 hematopoietic	 cells,	 while	 its	 overall	 efficacy	 in	 affecting	
disease	 activity	 in	 HIV‐1	 patients	 was	 considered	 low.154,	 155	 AMD3100	 exhibits	
furthermore,	poor	oral	bioavailability	mainly	due	 to	 the	 increased	positive	 charge	 (+2;	 in	
each	cyclam	ring	at	physiological	pH).		Accordingly,	the	development	of	AMD3100	into	drug	
for	 anti‐HIV	 application	 was	 discontinued,	 but	 it	 has	 since	 2008	 been	 in	 the	 market	
(Plerixafor	 or	Mozobil)	 as	 a	 drug	 for	 stem	 colony	mobilization,	 and	 it	 is	 administered	by	
subcutaneous	injection.156		
In	 subsequent	 attempts	 to	
improve	 oral	 bioavailability,	
compound	 AMD3465	 (2,	 Figure	
17)	 was	 developed	 by	
substitution	of	one	of	 the	cyclam	
rings	 in	 the	 precursor	






bioavailability	 was	 still	 low.	
Furthermore,	 replacements	 of	







discovery	 of	 potent	 compounds	WZ811	 (3)	 and	MSX‐122	 (4)	 (Figure	 17).	 The	 two	 latter	
compounds	 were	 found	 to	 block	 CXCR4	 at	 subnanomolar	 concentrations	 but	 failed	 to	
exhibit	a	good	pharmacokinetic	profile.159,	160	The	non‐cyclam	AMD‐analogue,	‐11070161	(5,	
Figure	 17),	 is	 a	 potent	 orally	 bioavailable	 CXCR4	 antagonist162	 shown	 to	 work	 in	 a	
synergistic	manner	with	other	HIV‐inhibitors	 such	as	 reverse	 transcriptase‐	and	protease	
inhibitors.	Due	 to	 liver	histology	 changes	and	high	 risk	of	hepatotoxicity	 found	 in	 animal	








FC131,	 suggesting	 that	 the	 conformational	 restriction	 of	 the	 cyclic	 backbone	 of	 FC131	 is	
essential	for	potency.	
Subsequently,	 Ueda	 et	al.167	 used	 a	 constrained	 and	 rigid	 indole	 template	 to	 incorporate	




scaffolding	 approach	 to	 develop	 tripeptidomimetic	 CXCR4	 antagonists	 based	 on	 key	 side	
chains	 of	 FC131,	 included	 a	 scaffold	 ring	 synthetically	 derived	 from	 diketopiperazine	
mimetics	 (compound	10,	 Figure	18).168	 This	 attempt	 resulted	however	 in	 very	 low	 to	no	
activity	in	comparison	to	the	reference	ligand	FC131.		
KRH‐1636	(11,	Figure	18)	is	another	low	molecular	weight	and	selectively	potent	inhibitor	
of	 CXCR4	 for	 X4	 HIV‐strains.169	 This	 ligand	 was	 previously	 considered	 to	 mimic	 the	
tripeptide	Arg‐Arg‐Nal	fragment	of	FC131,170	and	it	constitutes	an	important	prototype	for	
design	of	linear	peptidomimetics	as	CXCR4	antagonists	(as	exemplified	by	compound	12171	
in	Figure	18).	Furthermore,	KRH‐1636	 (11)	was	 found	 to	block	HIV	 replication	 in	vivo	 in	
28	
	
SCID	 mouse	 model	 while	 an	 intra‐duodenal	 administration	 in	 rats	 resulted	 in	 high	
bioavailability	suggesting	that	the	compound	might	be	orally	bioavailable.	However,	a	more	
conventional	 oral	 pharmacokinetic	 study	 in	 rats	 has	 not	 been	 reported.	 An	 alkyl	 amino	
analogue	 of	 KRH‐1636	 (KRH27315HCl;	 structure	 not	 disclosed	 yet)	 has	 high	
bioavailability	 (37%	 through	 oral	 administration	 in	 rats)	 and	 possesses	 potent	 CXCR4	
antagonistic	activity.171	A	key	challenge	for	effective	therapeutic	effect	and	development	of	
promising	candidates	 into	drugs	 remains	 the	achievement	of	 good	oral	bioavailability.	As	
already	 mentioned	 however,	 peptide	 mimetics	 are	 expected	 to	 possess	 improved	











The	 main	 aim	 of	 this	 project	 was	 to	 rationally	 develop	 tripeptidomimetic	 CXCR4	
antagonists	 based	 on	 the	 existing	 and	 generated	 knowledge	 about	 the	 SAR	 and	
pharmacophore	for	the	lead	cyclopentapeptide	CXCR4	antagonist	FC131.	An	additional	aim	



























substituted	 analogues	 of	 Arg1	 and	 Arg2	 (positions	 1	 and	 2)	 in	 FC131	 (Figure	 19).	




with	 a	 negatively	 charged	 receptor	 site.	 Contrary	 to	 position	 2	 however,	 the	 H‐bond	
potential	 (guanidino	 or	 amino),	 the	 stereochemistry	 (L	 or	 D),	 and	 the	 spacer	 properties	
(length,	degree	of	flexibility/rigidity)	were	not	found	as	critical.145	Gly	in	position	4	was	first	
utilized143	 with	 the	 intention	 to	 serve	 as	 a	
linker	 (linking	 the	 T140	 pharmacophoric	
residues,	 Figure	 16)	 during	 the	 construction	
and	screening	of	 libraries	to	discover	FC131.	
Reported	 SAR	 data143,	 150	 showed	 however	
that	 replacements	 of	 Gly	 led	 consistently	 to	
reduced	 potency	 compared	 to	 the	 parent	
ligand	 FC131.	 It	 is	 therefore	 suggested	 that	
the	 inherent	 flexibility	 and	 small	 size	 of	 Gly	
(due	 to	 the	 absence	 of	 side‐chain),	 enables	
conformations	 that	 are	 energetically	
unfavorable	 for	 other	 amino	 acid	
substitutions.		
However,	 existing	 SAR	 data	 for	 the	 two	
aromatic	 residues	 2‐Nal3	 and	 D‐Tyr5	 have	
been	 less	 informative.	 In	 a	 previously	 reported	 Ala‐scan	 of	 FC131,	 the	 Ala3	 and	 D‐Ala5	
analogues	were	both	classified	as	inactive;152	however,	the	roles	and	relative	importance	of	
the	 2‐Nal3	 and	 D‐Tyr5	 side	 chains	 have	 been	 unclear,	 leading	 to	 some	 ambiguity	 in	
Figure	 19.	 Schematic	 representation	 of	









The	 limited	 existing	 SAR	 data	 for	 position	 3	 (2‐Nal3)	 of	 FC131	 showed	 that	 substitution	
with	D‐2‐Nal	 (inverse	 stereochemistry)	 resulted	 in	 reduced	activity	 (by	25‐fold),143	while	
N‐methylation	 (N‐Me‐2‐Nal3),	 and	 substitution	 with	 a	 conformationally	 constricted	
tryptophan	(Trp)	derivative	 (Tricyclic)	 resulted	 in	 low,	and	no	activity	respectively.150,	 152	






















Thus,	 the	 existing	 SAR	 on	 position	 3	 are	 mostly	 directed	 on	 backbone	 effects	 (N‐




	Accordingly,	we	 probed	 the	 position	 3	 by	 preparing	 a	 series	 of	 analogues	with	 aromatic	
and	 aliphatic	 side	 residues	 of	 different	 size	 and	 shape	 affording	 a	 compound	 series	with	






























receptor	 interaction,	 the	 D‐Tyr5	 1‐angle	 will	 adopt	 one	 of	 these	 three	 possible	
conformations.	Clearly,	the	side	chain	conformations	are	critical	to	molecular	recognition.		
Therefore,	 in	 order	 to	 determine	 the	 3D	 rotamer	 state	 of	 D‐Tyr5	 in	 ‐space,	 i.e.	 the	 1‐
torsional	 angle	 and	 orientation	 of	 the	 side‐chain,	 we	 constructed	 a	 series	 of	
cyclopentapeptide	analogues	with	 conformationally	 constrained	position	5	 as	depicted	 in	






commercially	 available;	 thus,	D‐Phe5	 (compound	24)	was	used	as	 reference	 in	our	 assay.	
For	 compound	25,	 the	 achiral	 indane‐constrained	Aic5	was	 used	 to	 link	C	 to	 C.	Aic	 has	
been	previously	used	to	probe	the	orientation	of	aromatic	amino	acid	side‐chains,175‐177	and	
the	1‐angle	 is	 found	 to	prefer	 the	gauche	 (‐)	 (‐600),	and	 trans	 (1800)	 torsional	angles.	 In	
compound	26,	 C	was	 linked	 to	N	 using	D‐Tic,	which	was	 originally	 shown	 by	Hruby	 et	
al.178	to	limit	the	conformations	to	gauche	(‐)	or	gauche	(+),	excluding	trans.	For	compounds	
27	and	28,	we	originally	 intended	to	use	D‐Ppr	(a	proline	chimera)	 in	order	 to	adopt	 the	
trans	 and	 one	 of	 the	 gauche	 conformations	 (depending	 on	 which	 diastereomer	 is	 used)	
although,	trans	is	favoured	over	gauche.53	The	enantiomerically	pure	(3S)‐D‐Ppr	and	(3R)‐
D‐Ppr	were	not	commercially	available,	and	therefore	racemic	trans‐Ppr	(containing	(3S)‐
D‐Ppr	 and	 (3R)‐L‐Ppr)	 and	 cis‐Ppr	 (containing	 (3R)‐D‐Ppr	 and	 (3S)‐L‐Ppr)	were	 used	 as	
building	blocks.	Due	to	the	relatively	low	activity	of	these	analogues	(see	sub‐section	9.4.2)	
no	attempt	was	done	to	separate	or	synthesize	them	as	pure	(3S)‐D‐Ppr	and	(3R)‐D‐Ppr.	
Backbone	effects	 in	position	5.	Furthermore,	we	proceeded	 to	 isolate	 the	backbone	effects	
imposed	by	compounds	26‐28,	by	preparing	analogues	29	and	30	as	well	as	the	known	D‐








Synthesis	of	 the	 linear	pentapeptide	precursors	was	 carried	out	by	 standard	Fmoc‐based	
solid‐phase	peptide	synthesis	(SPPS)	using	a	trityl	resin	preloaded	with	Fmoc‐Gly,	based	on	
an	optimized	protocol	and	procedures	by	Chan.179	For	the	linear	precursors	of	macrocyclic	
compounds	(carrying	a	non‐Gly	 linker	residue),	 the	2‐Cl‐Trt	 resin	was	used	 for	 the	 initial	
loading	 of	 the	 spacer.	 In	 short,	 DIPEA	with	HBTU	were	 used	 to	 aid	 the	 coupling	 of	 each	
amino	acid,	and	20%	piperidine/DMF	was	used	for	Nα‐Fmoc	deprotections.	The	side‐chain	
protected	 peptide	was	 selectively	 cleaved	 from	 the	 resin	with	HFIP	 in	 DCM.	Head‐to‐tail	
cyclization	 was	 achieved	 in	 dilute	 solution	 (DMF:DCM,	 1:1)	 using	 PyBOP,	 and	 DIPEA,	











The	 antagonistic	 potency	 of	 the	 compounds	 in	 the	 present	 project	 was	 determined	 in	 a	




normal	 Gαi‐coupled	 signal	 into	 the	 Gαq	 signal;	 thus,	 the	 phospholipase	 C	 pathway	 is	
triggered	 and	 the	 receptor	 activation	 can	 be	 measured	 as	 PI‐turnover.180	 The	 IP3‐assay	
relies	on	the	 incorporation	of	 tritiated	[3H]	myo‐inositol	 into	 the	cells	 for	radiolabeling	of	
the	 PIP2	 turnover	 product	 IP3	 (3H‐IP3).	 Based	 on	 the	 method	 used	 to	 quantify	 the	
radiolabeled	IP3,	two	different	assays	were	used:	
SPA‐PI	 turnover	 assay.	 Following	 cell	 lysis,	 the	 extracts	 are	 mixed	 directly	 with	 yttrium	
silicate	 (Ysi)	 SPA	 beads.	 A	 radiolabeled‐IP3	molecule	 binds	 on	 a	 functional	 group	 on	 the	
scintillant	 material	 (Ysi),	 and	 the	 isotopes	 (3H)	 emit	 β‐rays,	 which	 in	 turn	 stimulate	 the	
fluoromicrosphere	 to	emit	 light.	The	rate	of	photons	in	unit	time	(CPM)	 is	measured	on	a	
scintillation	counter.	
Traditional	 IP3‐assay.	 Alternatively,	 a	 different	 assay	 (the	 “traditional”	 IP3‐assay	 which	
includes	an	anion‐exchange	chromatography	step)	was	used,	which	was	found	to	show	the	
same	 result.	 The	 extracts	 are	 filtered	 and	 purified	 on	 an	 anion	 exchange	 resin.	 After	











Compounds	with	 relatively	 small	 side‐chains	 in	 position	 3	 (14‐16	 and	23)	 had	 very	 low	
activity	 (>100	 μM)	 suggesting	 that	 the	 smaller	 size	 side‐chains	 prevent	 the	 formation	 of	






















All	 the	 constrained	 analogues	 25‐29	 (Figure	 23)	 showed	 moderate	 to	 low	 activity	
indicating	that	the	conformational	restriction	in	the	mobility	of	the	position	5	(side‐chain)	
is	not	well	accommodated	in	the	binding	site	of	CXCR4.	The	overall	effects	of	the	structural	


















the	 receptor‐binding	 pocket.	 Furthermore,	 Aic	 and	 D‐Tic	 in	 compounds	 25	 and	 26	
respectively,	constrain	the	2	angle	(see	Figure	4)	in	addition	to	1,	which	again	affects	the		




planarity	 of	 the	 phenyl	 ring.	 Also,	 the	N	 alkylation	 (compounds	26‐28)	 removes	 the	 H‐
bond	donor	ability	of	the	amide.	
	The	four	constrained	analogues	25‐28	appear	not	only	to	constrain	the	local	conformation	
of	 the	 side‐chain,	 but	 also	 to	 affect	 the	peptide	backbone	 conformation.	Accordingly,	 α,α‐







fold	 less	 potent	 relative	 to	 24,	 which	 indicates	 that	 the	 reduced	 size	 and	 increased	
conformational	flexibility	of	Gly5	partly	compensate	for	the	side	chain	removal.	





25	 (Gly5	 analogue)	 were	 built	 in	 Maestro	 183	 using	 our	 previously	 proposed	 bioactive	
backbone	conformation	for	cyclopentapeptide	CXCR4	antagonists170	as	input	structure.	
Protein	 preparation.	 The	 X‐ray	 crystal	 structure	 of	 CXCR4	 bound	 to	 the	 16‐mer	 peptide	
antagonist	 CVX15	 (PDB	 code	 3OE0)75	 was	 prepared	 and	 optimized	 with	 the	 Protein	
Preparation	Wizard	workflow184	as	previously	described145	(see	also	sub‐section	12.4.1).	
Docking	simulations.	The	three	ligands	were	docked	to	the	prepared	CXCR4	structure	using	
the	 induced	 fit	 docking	 workflow185	 which	 accounts	 for	 the	 conformational	 flexibility	 of	
both	 ligand	 and	 receptor	 using	 our	 optimized	 protocol.145	 	 Inspection	 of	 the	 generated	








To	 rationalize	 the	 SAR	 data	 for	
aromatic	 positions	 3	 and	 ‐5	 in	
cyclopentapeptide	 ligands,	
compounds	 13,	 24	 and	 25	 were	
docked	 to	 the	 X‐ray	 structure	 of	
CXCR4	 as	 described	 in	 the	
preceeding	sub‐section	(9.5.1).		
The	 proposed	 binding	 model	 for	
FC131	 is	 shown	 in	 Figure	 24.	 In	
comparison,	 the	 three	 docked	
ligands	 differing	 in	 position	 5	
(13:	 D‐Tyr5;	 24:	 D‐Phe5;	 25:	
Gly5),	 had	only	minor	differences	
among	 their	 top	 scoring	poses.	A	
superimposition	 of	 the	 three	
ligand	conformations	is	depicted	in	Figure	
25,	 indicating	 an	 overlap	 in	 the	 binding	
modes	 for	 the	 three	 ligands.	 Accordingly,	
the	2‐Nal3	 side‐chain	 is	 packed	 in	 a	well‐
defined	 hydrophobic	 subpocket	 mainly	
composed	 of	 residues	 in	 TMH	 5	 (Figure	
24).	 The	 restrictions	 of	 this	 subpocket	
would	explain	the	reduced	potency	of	the	
Xaa3	analogues	14‐23	(Figure	22).	The	D‐
Tyr5	 side‐chain	 in	 position	 5	 is	 oriented	
toward	 TMH	 1,	 and	 interacts	 with	





Figure	 24:	 Proposed	 binding	 mode	 for	 the	 lead	 FC131.	 Ligand	 in	





D‐Phe5,	while	 the	 4‐hydroxyl	 group	 forms	 an	 additional	H‐bond	with	Glu32,	which	would	
explain	 the	 higher	 activity	 of	 D‐Tyr5‐	 in	 comparison	 to	 the	 D‐Phe5	 analogue.	 The	 phenyl	
rings	of	13	and	24	are	solvent	exposed,	located	in	a	relatively	open	region,	and	the	lack	of	a	
defined	 subpocket	 for	 Xaa5	 would	 therefore	 explain	 why	 the	 D‐Tyr5	 side‐chain	 can	 be	















naphthyl	group	 in	position	3	(L‐2‐Nal3)	 is	 indispensable	for	activity.	The	 lack	of	a	defined	
binding	pocket	for	D‐Tyr5	in	line	with	previous	findings,150	imply	further	that	the	activity	of	
the	 cyclopentapeptides	 mainly	 resides	 in	 the	 remaining	 Arg1‐Arg2‐2‐Nal3	 tripeptide	
fragment.	 In	 an	 effort	 to	 further	 study	 the	 tripeptide	 fragment,	 based	 on	 present	 and	
previous	SAR	(see	also	section	9.1)	 the	naphthyl	group	and	the	L‐Arg2	 (position	2)	which	
both	 were	 found	 very	 sensitive	 to	 structural	 modifications,145,	 152	 were	 therefore	 kept	
constant.	
However,	 position	 1	 (Arg1)	 has	 been	 shown	 to	 be	 relatively	 tolerant	 to	 structural	
modifications,	 both	 with	 respect	 to	 stereochemistry	 (L‐	 or	 D‐arginine)	 and	 the	 chemical	
nature	 of	 the	 side	 chain.145,	 148	 Moreover,	 incorporation	 of	 a	 D‐amino	 acids	 in	 an	 all‐L	
sequence	 during	 cyclization	 have	 a	 turn‐inducing	 effect,186	 enhancing	 the	
macrolactamization	reaction	for	ring‐closure.		In	the	following	work,	we	therefore	decided	
to	 focus	 on	 the	 D‐Arg1	 epimers,	 using	 the	 lead	 cyclopentapeptide	 33	 (Figure	 26)	 as	 a	
starting	point.	










dissected	 to	 the	 linear	








focused	 on	 the	 Arg1‐Arg2‐2‐Nal3	 motif,	 using	 the	 D‐Arg1[FC131]	 analogue	 (33)	 as	 a	
reference	 compound	 (see	 also	 sub‐section	 10.1.1).	 Starting	 by	 dissection	 of	 the	
cyclopentapeptide	 structure	 we	 concluded	 (based	 on	 SAR,	 sub‐section	 10.3.1),	 that	 a	
further	 strategy	 should	 aim	 to	 reduce	 the	 undesired	 flexibility	 inherent	 in	 the	 linear	
analogues.	 Thus,	 herein	we	 reintroduced	 cyclic	 constraints	 (macrocycles)	 in	 a	 systematic	
manner	(Figure	27).		
Macrocyclization	i.e.	the	introduction	of	a	global	cyclic	constraint,	is	often	used	with	the	aim	
to	 force	 linear	 peptidic	 structures	 bearing	 pharmacophoric	 groups,	 into	 a	 bioactive	







specificity)187	 when	 designing	 bioactive	 compounds,	 and	 the	 term	 “macrocyclic	
peptidomimetics”	 has	 been	 used	 to	 describe	 such	 compounds.188	 The	 nature	 of	 the	
macrocyclic	 constraint	may	 vary,	 but	 typically	 the	macrocyclic	 peptidomimetics	 are	 part	
peptide	and	part	non‐peptide,	i.e.	built	on	a	hybrid	template.	
Thus,	 our	 objective	 is	 to	 force	 the	 D‐Arg1‐Arg2‐2‐Nal3	 motif	 into	 a	 more	 restricted	
conformation	 either	 by	 using	 a	 Gly‐Gly	 dipeptide	 spacer	 to	 give	 a	 simplified	
cyclopentapeptide	(compound	36),	or	by	using	5‐aminopentanoic	acid	(5‐Apa),	giving	the	























In	 solution	 preparation	 of	 linear	 compound	 34	was	 performed	 by	 means	 of	 a	 five‐step	
synthesis	 as	 depicted	 in	 Scheme	 3.	 Both	 HBTU	 and	 HATU	 were	 employed	 as	 activating	
reagents	 for	 the	 amide	 coupling	 reactions	 in	 presence	 of	 a	 tertiary	 base	 (DIPEA),	 and	 2‐
ethanolamine	was	used	for	accelerated	Fmoc‐group	deprotection.	Treatment	of	unit	B	with	






















34	displayed	moderate	 activity	with	 a	112‐fold	 lower	potency	 than	 the	parent	 ligand	33	
reflecting	 the	 extensive	 downsize	 of	 the	 cyclopentapeptide	 structure	 as	 well	 as	 the	














Compound	35,	was	 less	 active	 than	34,	 showing	 that	 the	 terminal	 amide	 groups	 are	 not	
contributing	favorably	to	activity.	
An	 apparent	 issue	 with	 the	 increased	 flexibility	 of	 such	 linear	 analogues	 is	 the	 negative	
contribution	 to	 the	 binding	 affinity	 for	 the	 receptor.187	 Thus,	 from	 a	 drug	 design	
perspective,	 a	 further	 optimization	 strategy,	 should	 aim	 to	 the	 introduction	 of	 more	
conformational	restriction	(see	10.1.2).		






2‐fold	 increase	 in	 potency	 relative	 to	 the	 linear	 analogue	 35	 (see	 Figure	 28),	 while	
simplification	 of	 36	 by	 replacement	 of	 Gly4‐Gly5	 with	 the	 flexible	 5‐Apa4	 hydrocarbon	
spacer	 (37,	 same	 ring	 size	 n=4)	 resulted	 in	 significantly	 reduced	 potency	 (>100	 μM).		
Accordingly,	the	contribution	from	the	Gly4‐Gly5	amide	bond	in	compound	36	 is	favorable	
to	activity,	either	by	a	geometrical	effect	or	through	direct	binding	interactions.	For	the	ring	
expansion/contraction	 strategy,	 analogues	 38‐40	 with	 ring	 expansion	 (n=5),	 and	 ring	
contraction	(n=3	and	n=2)	showed	lower	activity	than	36	(>100	μM).	However,	the	activity	




drug	 design	 context,	 the	 physicochemical	 properties	 of	 the	 former	 molecule	 are	
significantly	 improved	 through	 cyclization	 while	 the	 same	moderate	 activity	 is	 retained.	
Overall,	the	implication	is	that	ring	contraction	and	hence,	conformational	restriction,	could	
















obtained	 with	 moderate	 activity	 (sub‐section	 10.3.1).	 We	 further	 reintroduced	 cyclic	
constraints	 to	 reduce	 flexibility	 in	 the	 linear	 analogues,	 and	 successfully	 identified	 that	
activity	was	retained	in	the	smallest	ring‐size	analogue	(41,	10.3.2).		
A	 further	 consideration	 overall	 in	 our	 strategy	 to	 rationally	 design	 peptidomimetics	was	
our	 intention	 to	 retain	 an	 important	 characteristic	 of	 the	 reference	 cyclopentapeptides,	
which	 is	 the	 mimicry	 of	 peptide	 turns190	 (see	 also	 section	 3.2).	 Turns	 appear	 to	 be	 a	
common	ligand	recognition	element	for	peptides	and	GPCRs.191	Encouraged	by	the	activity	
of	41	(see	10.3.2)	we	proceeded	therefore	to	identify	a	more	constrained	scaffold	capable	of	
mimicking	 the	 turn‐structure	of	 the	parent	cyclopentapeptide	33;	 thereby,	presenting	 the	
side	 chains	 and	 backbone	 of	 the	 D‐Arg1‐Arg2‐2‐Nal3	 fragment	 in	 the	 required	 3D‐




orientation	 (topographical	 peptidomimetics).172	 Overall,	 we	 desired	 a	 more	 constrained	
and	rigid	skeleton	which	could	potentially	lead	to	more	drug‐like	candidates.		
11.1.2	Prototype	bicyclic	tripeptidomimetics	
In	 a	 pharmacophore‐based	 approach,	 design	 of	 such	 turn‐mimetics	 relies	 on	 the	
determined	bioactive	conformation	of	the	parent	(peptidic)	ligand.	We	therefore	employed	
our	previously	reported	a	3D	pharmacophore	model	that	describes	the	spatial	arrangement	
of	 the	 pharmacophoric	 side	 chains	 as	 well	 as	 the	 bioactive	 conformation	 of	 the	
cyclopentapeptide	 backbone.170	 We	 wanted	 to	 maintain	 the	 spatial	 orientation	 of	 the	
cyclopentapeptide	pharmacophore	by	using	a	template	which	would	not	extend	beyond	the	











A	 structural	 comparison	 of	 low	 energy	 conformations	 of	A	 with	 our	 3D	 pharmacophore	
model	indicated	that	side	chains	in	scaffold	A	were	oriented	in	a	similar	way	as	the	parent	
cyclopentapeptide	(Figure	31B).	
Two	 of	 the	 three	 stereocenters	 of	 Scaffold	A	 (Figure	 32)	 can	 be	 synthetically	 predefined	
(see	also	Chemistry),	and	therefore	two	diastereomeric	scaffolds	(A	and	A’	Figure	32A)	are	
considered.	An	overlay	of	low‐energy	conformations	of	the	two	scaffolds	(shown	in	Figure	




Figure	31.	A.	 Structure	 of	 scaffold	A;	B. Superimposition	 of	 a	
low‐energy	 conformation	 of	 A	 (grey	 carbon	 atoms)	 and	 the	
bioactive	 backbone	 conformation	 of	 the	 cyclopentapeptide	

















were	 targeted.	 The	 first	 pair	 (42	 and	 43)	 was	 based	 on	 use	 of	 cysteine	 and	 glycine	 to	
























undergoes	 condensation	 with	 adjacent	 amide	 nitrogen	 at	 the	 backbone	 to	 form	 the	 N‐
acyliminium	 ion	 intermediate	 B.	 Furthermore,	 nucleophilic	 attack	 from	 the	 deprotected	












Stereoselective	 cyclization:	 In	 a	 study	 by	 Grimes	 et	 al.,194	 it	 was	 concluded	 that	 the	
cyclization	 step	 occurs	 stereoselectively;	 the	 configuration	 at	 the	 bridgehead	 (C‐9a)	
depends	 on	 the	 configuration	 at	 C‐3,	 and	 in	 the	 absence	 of	 a	 R1	 substituent	 on	 the	
configuration	 at	 C‐6.	 Accordingly,	 the	 R1	 substituent	 (at	 C‐3)	 has	 an	 influence	 on	 the	
stereodirection	of	 cyclization	with	 si	 attack	 favored,	 giving	a	cis	 relationship	between	H9a	
and	H3	(Figure	34).	In	the	absence	of	R1	substitution	at	C‐3,	the	substituent	at	C‐6	(R2)	exerts	
some	 effect	 on	 the	 stereoselectivity,	 and	 the	 predominating	 effect	 favors	 the	 result	 of	 si	
attack	with	trans	relationship	between	H6	and	H9a.194	The	assigned	stereochemistry	by	NMR	
on	 the	obtained	bicycles	 (42‐45	 including	unpublished	data)	was	 in	 agreement	with	 this	
proposed	outcome.	
















Unit	 D	 (Scheme	 4)	 was	 commonly	 prepared	 through	 N‐alkylation	 of	 the	 aromatic	
ethylamine	using	bromoacetaldehyde	dimethyl	acetal	as	depicted	in	Scheme	5.	Moreover,	a	
protected	 Arg	 residue	was	 used	 as	 unit	 E	 in	 the	 synthesis	 of	 the	 prototypes	42‐45.	 The	
synthetic	 strategy	employed	 in	 the	preparation	of	unit	F	varied	according	 to	 the	 targeted	
R1‐side	chain	structure.	
Synthesis	of	analogues	42	and	43.	For	analogues	42	and	43	(see	Figure	33	for	structures),	
Fmoc‐Cys(Trt)‐OH	 (L‐configuration	 for	 42,	 and	 D‐configuration	 for	 43)	 was	 used	 in	
conjunction	with	 a	 guanidinylated	 glycin	 (51,	Scheme	5)	 for	 the	 incorporation	of	R1‐side	
chain	 (for	 illustration,	 see	 synthesis	 of	 42	 in	 Scheme	 5).	 51	 was	 prepared	 by	
guanidinylation	 of	 glycin	 methyl	 ester	 hydrochloride	 using	 N,N‐di‐Boc‐1H‐pyrazole‐1‐
carboxamidine	followed	by	hydrolysis	of	the	methyl	ester	of	the	resulting	50	using	LiOH	in	
a	mixture	of	water	 and	 acetone.195,	 196	 In	brief,	 synthesis	 of	 analogue	42	 (Scheme	5)	was	
achieved	 through	 the	 alkylation	 of	 2‐(naphthalene‐2‐yl)ethanamine	 with	
bromoacetaldehyde	 dimethyl	 acetal	 in	 refluxing	 THF	 to	 give	 secondary	 amine	 46.	 This	
amine	 was	 in	 turn	 coupled	 with	 Fmoc‐protected	 arginine	 to	 give	 47.	 Further	 Fmoc‐
deprotection	 and	 coupling	 with	 appropriately	 protected	 L‐cysteine	 gave	 48,	 which	 was	
submitted	to	another	Fmoc‐deprotection,	and	then	coupled	with	carboxylic	acid	51	to	give	
the	 linear	 precursor	 49.	 Treatment	 with	 TFA,	 thioanisole	 and	 water	 facilitated	 global	
deprotection	 leading	 to	 formation	 of	 the	 acyliminium	 ion	 intermediate	 that	 after	
52	
	
nucleophilic	 attack	 by	 the	 thiol	 gave	 target	 compound	 42.	 Similarly	 compound	 43	 was	
prepared	using	D‐cysteine	to	prepare	the	intermediate	product	48.	Upon	deprotection	and	
cyclization,	the	configuration	of	 the	newly	 formed	stereocenters	of	42	and	43	 (see	Figure	
33)	were	determined	using	the	2D	1H	ROESY	experiment.	The	known	configurations	of	C‐6	



















inseparable	 mixture	 of	 diastereoisomers.	 After	 deprotection	 of	 53	 and	 cyclization	 (as	
previously	described	for	42)	the	amine	group	(R1	side	chain)	was	guanidinylated	to	give	44	





toluene,	 110	 C;	 (c)	 Boc2O,	 Et3N,	 DMAP,	 CH2Cl2/DMF;	 (d)	 Ph3CSH,	 Et3N,	 CH2Cl2;	 (e)	 1M	 aq.	 LiOH,	 THF;	 (f)	













Compounds	 42	 and	 43	 exhibited	
low	 to	 no	 activity	 (>100	 μM),	 and	
the	 lower	 activity	 than	 44	 and	 45	
can	 be	 therefore	 attributed	 to	 the	
peptide	 bond	 introduced	 in	R1	 side	
chain.	 The	 planarity	 of	 the	 amide	
bond	 in	 combination	 with	 a	
conformationally	 constrained	 R1	
side	chain	had	an	unfavorable	effect	
on	 the	 biological	 activity	 of	42	 and	43.	 Clearly,	 keeping	 the	 structural	 and	 topographical	
identity	of	 the	key	side	chains	 intact	 (as	 in	compounds	44	 and	45),	appeared	to	be	more	
beneficial	for	biological	activity.	
Furthermore,	 compounds	44	 and	45	 which	 have	 opposite	 stereochemistry	 in	 two	 of	 the	
three	 chiral	 centers	 ((3R,	 9aS,	 6S	 and	 3S,	 9aS,	 6S	 respectively),	were	 found	 to	 be	 almost	
equipotent.	This	suggests	that	 the	D‐/L‐	configuration	of	R1	sidechain	does	not	contribute	
significantly	 to	 the	 receptor	 binding	 conformation	 of	 these	 ligands;	 which	 is	 further	
supported	 by	 the	 comparison	 of	 low‐energy	 conformations	 of	 the	 two	 diastereomeric	
scaffolds	 displaying	 their	 side	 chains	 in	 similar	 orientations	 (Figure	 32).	 Overall,	 the	
scaffold‐based	 tripeptidomimetics	44	 and	45	 are	significantly	 less	potent	 than	the	parent	
cyclopentapeptides	 (FC131	 and	 D‐Arg1[FC131])	 that	 they	 are	 based	 on;	 considering	
however,	 the	 rather	 extensive	 structural	 change	 through	 this	 scaffold‐hop,	 the	 obtained	
analogs	represent	promising	`hits´.	
	In	two	earlier	attempts	to	develop	scaffold‐based	peptidomimetic	CXCR4	antagonists	(see	
sub‐section	 7.2.2,	 Figure	 18,	 compounds	 9,	 10),167,	 168	 a	 drop	 in	 activity	 for	 initial	
compounds	compared	to	the	highly	optimized	FC131	was	also	found.	This	 further	reflects	
the	 general	 complexity	 of	 the	 initial	 “scaffold	 hop”	 for	 prototype	 compounds.	 Further	
studies	 into	 the	 optimal	 chain	 length	 for	 the	 three	 substituents	 and	 the	 nature	 of	 the	






pharmacophoric	 side	 chains,	 is	 currently	 in	 progress	 (see	 section	 11.4).	 These	 studies	
should	provide	 further	 insight	 into	 the	potential	of	 the	 scaffold	 reported	herein,	and	SAR	
data	will	be	reported	in	due	course.	
11.4		Additional	compounds	
Based	 on	 the	 collective	 knowledge	 on	 the	 pharmacophore	 and	 SAR	 for	 the	 cyclic	
pentapeptide	 analogues	 in	 conjunction	with	 the	 novel	 hits	 represented	 by	 the	 prototype	
compounds	44	and	45	 (Figure	33),	additional	bicyclic	analogues	have	been	designed,	and	
synthesized	in	the	course	of	the	present	project	and	considerable	time	and	effort	has	been	
devoted	 to	 this	 work.	 Presently,	 11	 new	 analogues	 (including	 diastereomers)	 have	 been	
prepared	 and	 purified;	 there	 are	 now	 in	 various	 stages	 with	 respect	 to	 structure	
determination	(NMR)	and	biological	evaluation.	The	design,	synthesis,	characterization	and	


















After	 its	discovery169	 in	2003,	 very	 little	 is	 known	about	 the	prototype	CXCR4	antagonist	
KRH‐1636.	 In	 order	 to	 investigate	 the	 importance	 of	 the	 different	 functionalities	 of	 this	
potent	 antagonist	 (compound	54,	Figure	 37),	we	 first	 carried	 out	 a	 limited	 SAR	 study.	 A	































	The	CXCR4	antagonistic	potency	of	54‐59	 along	with	 the	 lead	compound	KRH‐1636	was	
assessed	 in	 a	 functional	 assay	 as	 described	 in	 section	 9.3.	 Analogue	57,	displayed	 lower	
potency	 (by	17‐fold)	 compared	 to	54	 indicating	 the	 importance	of	 the	 pyridine	nitrogen.	
The	 pyridine	 ring	 was	 further	 removed	 affording	 a	 free	 amine	 in	 analogue	 58,	 which	
showed	 somewhat	 lower	 potency	 than	 57	 revealing	 thus,	 the	 role	 of	 the	 pyridine‐2‐
ylmethyl	group.	Moreover,	 removal	of	 the	amino	group	 in	59	 had	a	detrimental	effect	on	
activity,	confirming	the	charged	secondary	amine	group	as	indispensable	part	of	the	KRH‐
1636	 pharmacophore.	 A	 significant	 loss	 in	 activity	 compared	 to	 parent	 ligand	 54	 was	
furthermore	 found	 for	 both	 compounds	 55	 and	 56,	 with	 modifications	 in	 R2‐	 and	 R3‐
positions,	 respectively;	 thus,	 the	positive	 charge	of	 the	guanidine	group	and	 the	aromatic	
moiety	(naphthyl)	are	essential	pharmacophoric	elements.	
In	short,	the	results	from	this	initial	SAR	study	suggested	that	the	aromatic	group,	the	Arg,	









(Scheme	 7)	 with	 methyl	 4‐bromomethyl	 benzoate,	 to	 give	 carboxylic	 acid	 (64)	 after	
hydrolysis	 of	 the	 methyl	 ester	 (63).	 Coupling	 of	 the	 two	 halves	 was	 facilitated	 by	






















After	 standard	 workup,	 all	 intermediate	 products	 were	 purified	 by	 flash	 column	
chromatography	on	silica	gel,	and	final	products	were	purified	by	RP‐HPLC	and	lyophilized.	
12.3	Site‐directed	mutagenesis		
Mutagenesis	 studies	 were	 carried	 out	 in	 order	 to	 experimentally	 determine	 key	 binding	
interactions	 of	 KRH‐1636	 with	 the	 CXCR4	 receptor.	 Residues	 previously	 found	 to	 be	
involved	 in	 the	 binding	 modes	 of	 FC131,145,	 200,	 201	 as	 well	 as	 cyclam‐based	 CXCR4	
antagonists	 (AMD3100	 and	 analogues)202‐204	 were	 selected,	 and	 a	 library	 of	 24	 CXCR4‐
mutants	was	constructed.	Most	of	the	mutations	included	a	replacement	with	Ala;	however,	
certain	acidic	 residues	 such	as	Asp	were	alternatively	 subjected	 to	 isosteric	 substitutions	














1636	 antagonistic	 potency	 was	 significantly	 reduced	 upon	 mutations	 of	 TMH	 3	 residue	
His113,	TMH	6	residue	Asp262	and	TMH	7	residue	His281	(Table	1).	Moreover,	the	potency	of	
KRH‐1636	was	also	reduced	upon	mutations	of	Tyr45,	Asp171,	and	Gln200	in	TMH	1,	‐4	and	‐5,	




analogs	 57	 and	 58	 (Figure	 35)	 were	 also	 included	 in	 the	 mutagenesis	 study	 to	 further	
investigate	 the	 molecular	 interactions	 of	 the	 structurally	 modified	 R1‐side	 chain	 for	 the	
three	analogs	with	CXCR4.		
	Interpretation	 of	 the	 functional‐SDM	 data	 (Table	 1)	 for	 all	 three	 ligands	 indicated	
furthermore,	that	mutations	in	TMHs	1‐4	and	ECL‐2	affected	the	potency	of	the	ligands	in	a	
similar	manner,	while	several	of	the	mutations	in	TMHs	5‐7	affected	the	three	ligands	in	a	
distinctive	manner.	 In	 sum,	 the	 overall	 trend	 identified	 in	 the	 functional	 experiments	 for	
analogues	54,	57	and	58	(Table	1)	suggests	that	the	structurally	distinct	R1	group	contacts	
TMHs	5‐7.	
The	 CXCR4‐mutants	 H113A‐,	 D171N‐,	 D262N‐	 and	 H281A‐CXCR4	 were	 consistently	
reported	to	be	involved	in	the	binding	modes	of	other	prototype	CXCR4	antagonists	such	as	





receptor	 (see	 Table	 1;	 similar	 potencies	 to	 the	 wt‐CXCR4	 receptor	 were	 observed),	 the	
E288A,	D97A,	D187A,	W94A	and	Y116A	mutants	reduced	the	potency	of	CXCL12	to	activate	
the	receptor	by	an	8‐14	fold	reduction	(Table	1).	

















Table	1.	Functional	data.	Fmut	 indicates	 the	 difference	between	 the	 potency	on	wt‐	 and	mutant	CXCR4.	
Red	 indicates	 Fmut	 >25,	 orange	 indicates	 Fmut	 from	 10‐25,	 while	 yellow	 indicates	Fmut	 from	 5‐10	
and	green	indicates	Fmut	<0.5.	
	
   Positiona     Number EC50 Fmut EC50 Fmut EC50 Fmut EC50 Fmut
nM μM μM μM
wt CXCR4 1,5 1,0 0,50 1,0 8,5 1,0 12 1,0
TM‐1 I:07/1.39 Y45A 3,4 2,3 4,0 8,0 56 6,6 181 15
II:20/2.60 W94A* 18 13 0,06 0,12 0,6 0,07 0,64 0,05
II:23/2.63 D97A* 20 14 0,21 0,41 0,54 0,06 1,4 0,12
TM‐3 III:05/3.29 H113A* 0,84 0,58 13 26 > 100 > 100
III:08/3.32  Y116A*
III:09/3.33 T117A 1,7 1,17 0,17 0,34 0,87 0,10 1,4 0,12
TM‐4 IV:20/4.60 D171N* 3,2 2,2 2,7 5,3 68 8,1 231 20
Cys+1 D187A 13 9 0,35 0,69 4,1 0,49 5,4 0,46
Cys+2 R188A 0,53 0,36 0,86 1,7 8,4 0,99 25 2,1
Cys+3 F189A 1,8 1,2 0,13 0,26 0,74 0,09 1,0 0,09
Cys+4 Y190A 1,2 0,82 0,27 0,53 12 1,4 12 1,01
V:01/5.35 V196A 1,4 0,96 1,4 2,8 4,2 0,50 13 1,1
V:04/5.38 F199A 1,4 0,98 0,69 1,4
V:05/5.39 Q200A 1,4 0,9 3,7 7,4 17 2,0 250 21
V:05/5.39 Q200W 1,8 1,2 10 21 14 1,6 85 7,2
V:08/5.42 H203A 1,4 1,0 0,71 1,4
VI:13/6.48 W252A 0,78 0,53 3,8 7,5 27 3,2 173 15
VI:16/6.51 Y255A 1,1 0,77 1,7 3,3
VI:20/6.55 I259A 2,1 1,4 2,6 5,1
VI:20/6.55 I259W 1,3 0,91 1,5 2,9
VI:23/6.58 D262N* 5,8 4,0 13 26 27 3,2 11 0,9
VII:‐02/7.32 H281A* 1,8 1,2 31 61 53 6,2 155 13
VII:02/7.35 I284A 2,3 1,6 3,4 6,7 34 4,0 306 26


































Method.	 Competition	 binding	 experiments	 were	 carried	 out	 with	 [125I]‐12G5	 used	 as	
radioligand,	 on	 transiently	 transfected	COS‐7	 cells.	The	affinity	was	determined	based	on	




of	 CXCL12	 in	 the	 five	 (W94A,	 E288A,	 D97A,	 D187A,	 Y116A)‐CXCR4	 mutants,	 and	 the	
monoclonal	antibody	12G5	was	used	to	assess	the	ligand	affinity.	In	addition	to	these	five	
mutants,	 a	 number	 of	mutations	 found	 to	be	 important	during	 the	 functional	 assay	were	
also	 included	 (Table	 2).	 All	 mutants	 had	 close	 to	 wild‐type	 receptor	 affinities	 for	 12G5	
suggesting	that	they	did	not	affect	the	receptor	cell	surface	expression.		
	Despite	 the	 strong	 antagonistic	 potency	 measured	 in	 the	 functional	 assay,	 KRH‐1636	
displayed	lower	binding	affinity	in	wt‐CXCR4	measured	against	125I‐12G5	(Figure	39).	This	
further	 suggests	 that	 this	 compound	 and	 the	 two	 derivatives	 bind	 allosterically	 to	 the	
Figure	38.	Effects	of	H113A,	D171N,	H281A	and	D262N	on	







lower	 affinity	 (Figure	 39)	 in	 comparison	 to	 KRH‐1636	 for	 the	 wt‐CXCR4,	 and	 were	
therefore	rendered	unfit	for	further	binding	experiments.		
The	 affinity	 of	 KRH‐1636	 determined	 against	 125I‐12G5,	 was	 strongly	 affected	 in	 cells	
expressing	 the	TMH	3	mutants	H113A	and	Y116A,	TMH	4	mutant	D171N,	TMH	5	mutant	
D262N,	 and	 the	 two	 mutations	 in	 TMH	 7,	 H281A	 and	 E288A.	 Accordingly,	 the	
aforementioned	 mutations	 reduced	 the	 IC50‐values	 8‐	 to	 >12‐fold	 in	 respect	 to	 the	 wt‐
CXCR4	(Table	2).	Furthermore,	KRH‐1636	could	not	displace	12G5	in	the	Y116A‐mutant.	In	
line	with	 the	 functional	 data	 on	 antagonistic	 potency,	 residues	 His113,	 Asp171,	 Asp262	 and	











IC50 Fmut IC50 Fmut
(nM) (µM)
wt CXCR4 4,7 1,0 8,0 1,0
II:20/2.60 W94A 1,9 0,40 1,7 0,21
II:23/2.63 D97A 9,4 2,0 8,5 1,1
III:05/3.29 H113A 2,7 0,6 > 100 >12
III:08/3.32 Y116A 8,7 1,9
TM‐4 IV:20/4.60 D171N 2,2 0,47 67 8,3
ECL‐2 Cys+1 D187A 16 3,4 26 3,2
TM‐6 VI:23/6.58 D262N 3,7 0,79 > 100 >12
VII:‐02/7.32 H281A 2,4 0,52 63 7,8








Figure	 39.	 Binding	 affinity	 of	 KRH‐
1636	and	R1	analogues	57	and	58	in	











protein	 structure	 using	 the	 induced‐fit	 docking	 protocol.185	 All	 molecular	 modeling	
calculations	 were	 performed	 using	 the	Maestro	 software	 packages	 (Schrödinger,	 U.S).183	
12.4.1	Procedures	
Protein	 preparation.	 The	 X‐ray	 structure	 of	 human	 CXCR4	 bound	 to	 the	 16‐mer	 peptide	
antagonist	 CVX15	 (PDB	 code	 3OE0)75	 was	 imported	 and	 prepared	 with	 the	 Protein	
Preparation	Wizard	workflow.184	Using	the	preprosessing	tool,	bond	orders	were	assigned,	










rotamers).	 The	 binding	 cavity	 was	 first	 defined	 with	 the	 enclosing	 box	 (26Å	 length)	
centered	 on	 Asp187.	 The	 standard	 precision	 (SP)	 scoring	 function210	 was	 applied	 in	 the	













in	 agreement	 with	 the	 experimental	 data.	 In	 the	 proposed	 binding	model	 for	 KRH‐1636	
(Figure	40),	the	R1‐side	chain	adopts	a	bending	conformation	around	the	secondary	amino	
group;	the	pyridine	and	phenyl	rings	lie	in	the	same	plane,	and	the	R1‐side	chain	is	globally	
oriented	 toward	 the	 TMH	 6‐7	 region.	 The	 TMH	 7	 residue	 His281	 forms	 an	 aromatic	 π‐π	
stacking	 interaction	with	 the	 pyridine	 ring,	 and	 the	 TMH	 6	 residue	 Asp262	 is	 involved	 in	
bimodal	interactions	with	the	charged	secondary	amine	of	the	R1‐side	chain	in	KRH‐1636.	
Furthermore,	 a	 water‐mediated	 interaction	 of	 Glu288	 with	 the	 ligand	 backbone,	 an	
interaction	 of	 Gln200	 with	 Asp262,	 and	 a	 ligand‐backbone	 interaction	 with	 Arg188	 were	
detected.	
	 	
Figure	40.	A.	Binding	conformation	of	KRH‐1636	 in	 the	CXCR4	crystal	 structure	as	calculated	by	










Asp262,	 and	 His281.	 The	 antagonistic	 potency	 of	 KRH‐1636	 was	 also	 found	 to	 depend	 on	
Tyr45	and	Gln200,	while	binding	affinity	was	also	strongly	affected	by	mutation	of	Tyr116	and	
Glu288.	 The	 experimental	 data	 in	 conjunction	 with	 the	 derived	 binding	 model	 from	 the	
docking	simulations	suggest	therefore	that	the	L‐Arg	guanidino	group	of	KRH‐1636	forms	





the	 binding	 mode	 of	 KRH‐1636213	 suggested	 an	 interaction	 pattern	 involving	 receptor	
residues	Asp262,	Glu288	and	Asp171;	which	resembles	the	proposed	binding	mode	of	another	
potent	 CXCR4	 antagonist,	 the	 AMD3100202,	 214	 (compound	 1,	 Figure	 16).	 However,	 the	
study213	 was	 merely	 based	 on	 homology	 modeling,	 using	 the	 bovine	 rhodopsin	 crystal	
structure	 as	 a	 template,	 which	 is	 a	 suboptimal	 representation	 of	 CXCR4,215	 without	
including	 any	 experimentally	 determined	 ligand‐receptor	 interactions.	 Our	 own	 study	
provides	first	experimental	evidence	to	describe	the	binding	of	KRH‐1636	on	CXCR4	based	
on	SAR,	 site‐directed	mutagenesis,	 and	molecular	docking	on	 the	CXCR4	crystal	 structure	
suggesting	thus,	a	more	accurate	binding	model	for	this	non‐peptide	antagonist.	
Furthermore,	 it	 was	 recently	 suggested	 a	 binding	 mode	 for	 FC131	 based	 on	 ligand	
structure‐	activity	studies,	SDM	and	in	silico	docking	to	the	X‐ray	structure	of	CXCR4.216	The	
proposed	 receptor	 interactions	 for	 the	Arg2	guanidino	group	 in	FC131	(His113,	Thr117,	 and	
Asp171)	are	consistent	with	the	interactions	of	the	R2‐guanidino	group	in	KRH‐1636	in	our	











antagonist	 CVX15	 in	 complex	 with	
CXCR475	 (model	 comparisons	 not	
shown)	 indicated	 the	 same	 pattern	




in	 FC131	 (Figure	 41),	 and	 only	 the	
central	 arginine	 (Arg2)	 of	 CVX15	
appears	 to	 overlap	 well	 with	 the	
guanidine	group	of	KRH‐1636.	
Moreover,	 our	 present	 binding	
model	 indicates	 that	 the	 R1	 side‐
chain	of	KRH‐1636	shares	common	
binding	 interactions	 with	 the	
previously	 reported	 binding	 mode	
of	the	potent	CXCR4	antagonist	and	AMD‐series	analogue	‐3465.	This	monocyclam	analogue	










Figure	 41.	 Superimposition	 of	 binding	 conformations of	
KRH‐1636	and	FC131	 in	the	CXCR4	crystal	structure;	KRH‐







 Our	 SAR	 data	 for	 the	 aromatic	 residues	 of	 the	 lead	 cyclopentapeptide	 and	 CXCR4	
antagonist	 FC131	 showed	 that	 the	 naphthyl	 group	 (2‐Nal,	 position	 3)	 is	 generally	
more	important	for	activity	than	the	phenol	group	in	position	5	(D‐Tyr5).	Molecular	
modeling	 indicated	 further,	 the	 lack	 of	 a	 defined	 binding	 pocket	 for	 D‐Tyr5	
suggesting	that	this	residue	is	dispensable	for	activity.	
	
 Our	 collective	 SAR	 data	 suggested	 that	 tripeptidomimetics	 could	 be	 based	 on	 the	
Arg1‐Arg2‐2‐Nal3	 fragment,	 and	 novel,	 scaffold‐based	 tripeptidomimetics	 were	
investigated	in	this	project.	
	
 KRH‐1636	has	been	previously	assumed	 to	exhibit	a	 similar	molecular	 recognition	
pattern	 as	 FC131.	 Subsequently,	 site‐directed	 mutagenesis	 to	 map	 the	 ligand‐
receptor	interactions	in	conjunction	with	molecular	docking	suggested	that	that	the	
central	arginine‐guanidino	group	of	KRH‐1636	has	overlapped	receptor	interactions	
with	 the	 Arg2	 of	 FC131;	 however,	 the	 naphthyl	 rings	 of	 the	 two	 ligands	 have	
reversed	coordinates	in	the	receptor	binding	site.	
				 	 	
 From	 the	 existing	 and	 generated	 SAR	data	 on	 FC131,	 peptidomimetic	 drug	 design	
could	potentially	be	based	on	a	minimal	recognition	motif,	the	dipeptide	Arg2‐2‐Nal3	
fragment,	 which	 could	 serve	 as	 a	 starting	 point	 for	 future	 design	 of	
dipeptidomimetics	as	CXCR4	antagonists.		
	
 Biological	 testing	 of	 the	 prototype	 bicyclic	 tripeptidomimetics	 showed	 that	 they	
represent	promising	candidates	for	further	structural	tuning	and	optimization.	The	
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